DRAWINGS

Figure 1:




Figure 2:



Overall survival (OS)
Probability of survival
1.00
0.75
0.50
0.25
0.00
Cabozantinib + Compound A
Cabozantinib
Compound A
Vehicle
TREATMENT
Cabozantinib + Compound A
Cabozantinib
Compound A
Vehicle
0
20
40
60
Vehicle 76 76 70 57 46 34 31 23 20 14 12 11 8 8 8
Compound A 73 73 66 64 53 45 41 34 32 28 25 22 20 20 18
Cabozantinib + CompA 72 72 72 72 72 68 66 61 60 58 57 52 50 49 48
Cabozantinib 75 75 75 73 71 64 58 52 51 47 44 44 42 39 39
0
20
40
60
Time until tumor progression [days]

Figure 3:



RCC PDX model RXF2796
Vehicle
Cabozantinib 10 mg/kg QD p.o.
Compound A 100 mg/kg QD p.o.
Compound A + Cabozantinib
Body weight change [%]
mean +/- SEM
20
15
10
5
0
-5
-10
-15
-20
0
10
20
30
40
50
60
70
Days after treatment start

Figure 4:



Progression Free Survival (PFS)
TREATMENT
Axitinib + Compound A
Axitinib
Compound A
Vehicle
Probability of survival
1.00
0.75
0.50
0.25
0.00
Axitinib + Compound A
Axitinib
Vehicle
Compound A
0
20
40
60
Vehicle 76 44 6 1
Compound A 73 41 12 5 1 1
Axitinib + CompA 72 56 28 17 13 9 8 8 6 5 4 3 3 3
Axitinib 74 54 20 11 8 3 3 1 1 1 1 1 1 1
0
20
40
60
Time until tumor progression [days]

Figure 5:




Overall survival (OS)
Probability of survival
1.00
0.75
0.50
0.25
0.00
Axitinib + Compound A
Axitinib
Compound A
Vehicle
TREATMENT
Axitinib + Compound A
Axitinib
Compound A
Vehicle
0
20
40
60
Vehicle 76 76 70 57 46 34 31 23 20 14 12 11 8 8 8
Compound A 73 73 66 64 53 45 41 34 32 28 25 22 20 20 18
Axitinib + CompA 72 72 72 71 70 69 65 60 56 54 52 49 45 45 44
Axitinib 74 74 74 70 70 65 62 55 50 47 43 41 37 34 33
0
20
40
60
Time until tumor progression [days]

Figure 6:


RCC PDX model RXF2717
Vehicle
Axitinib 4 mg/kg BID p.o.
Compound A 100 mg/kg QD p.o.
Compound A + Axitinib
Body weight change [%]
mean +/- SEM
20
15
10
5
0
-5
-10
-15
-20
0
10
20
30
40
50
60
70
Days after treatment start